Axial - Cipher #7 (bispecifics)

Finding the other half

Analysis of public clinical and business development data in life sciences.

Bispecifics are protein therapeutics that engage T-cells with a target; recently showing tremendous amount of growth in the clinic and research:

Source: BioCentury

With Regeneron being the largest leader in the field:

Source: Regeneron

Where the average bispecific deal value increasing over time and a share increase in the number of partnerships in 2014/2015 when cell therapies were getting approved and bispecifics were seen as a viable/lower cost alternative:

With the deals focused on oncology:

And development and licensing agreements:

Focused on discovery and preclinical work:

With deals having no geographic preference:

Thank you.